Worldwide Clinical Trials supports breast cancer programs from Phase I development through registrational studies across biomarker-defined patient populations, including HR+, HER2+, and HER2-low. We also bring expertise in next-generation treatment modalities, including ADCs, bispecific antibodies, and cell therapy/CAR T. To help you execute these trials successfully, you need strong biomarker-driven patient identification and enrollment, molecular testing strategies, and complex trial design in a highly competitive recruitment landscape. Our dedicated oncology business unit averages 11+ years of experience and an industry-leading 90%+ retention rate, so our seasoned, specialized team supports your study end to end.
Read our fact sheet to learn more about our breast cancer expertise, including:
- 40+ breast cancer studies with 4,300+ patients enrolled across 350+ unique sites, globally
- Global footprint spanning North America, Europe, Asia-Pacific, Latin America, and the Middle East and North Africa
- Expertise in next-generation modalities, from ADCs and bispecific antibodies to hormone antagonists, kinase inhibitors, and cancer vaccines
- Flexible, data-centric solutions with best-in-class technologies, visual analytics, and rapid startup
